While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

Though prescribing climate-friendly inhalers is environmentally sound, some experts warn certain patients may be overlooked.

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...

Under the leadership of Pam Cheng, the company’s chief sustainability officer, Breztri may soon be released in a new package ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Respiratory Inhaler Devices MarketThe global respiratory inhaler devices market, valued at USD 37,258.5 million in 2023, is projected to grow at a compound annual growth rate (CAGR) of 4.90%, reaching ...

The medications include GLP-1 drugs such as Ozempic from Novo Nordisk and Trulicity from Eli Lilly, and SGLT2 drugs such as Jardiance from Boehringer Ingelheim and Eli Lilly and Farxiga from ...

The integration of AI into drug submission and approval processes signifies a shift towards more efficient pharmaceutical development. The potential benefits are substantial, including faster ...

Other pharmaceutical players such as Roche, Amgen, Pfizer, AstraZeneca and Boehringer also have obesity drugs in the pipeline ...